Assessing the role of oestrogen in the prevention of cardiovascular disease

Annals of Medicine

Volumn 33, Issue 5, 2001, Pages 305-312

  Nair, G V ^a   Klein, K P ^a   Herrington, D M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Menopause; Oestrogen; Women

Indexed keywords

CHOLESTEROL; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0034920552     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890109002082     Document Type: Review

References (55)

1. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women
2. Hormone therapy to prevent disease and prolong life in postmenopausal women
3. Prospective study of exogenous hormones and risk of pulmonary embolism in women
4. How do we explain the clinical benefits of estrogen? From bedside to bench
5. Cardiac myocytes and fibroblasts contain functional estrogen receptors
6. The protective effects of estrogen on the cardiovascular system
7. 17 beta-estradiol prevents programmed cell death in cardiac myocytes
8. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
9. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease
10. Use of replacement estrogens and the risk of myocardial infarction
11. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women
12. Noncontraceptive estrogens and myocardial infarction in young women
13. Hormone replacement therapy for secondary prevention of coronary heart disease
14. Postmenopausal hormones and recurrence of coronary events in the Nurses' Health Study
15. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
16. Early risks of hormone therapy in patients with coronary heart disease
17. The Coronary Drug Project: Findings leading to discontinuation of the 2.5 mg/day estrogen group
18. Risk of venous thromboembolism in users of hormone replacement therapy
19. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
20. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
21. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe
22. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study
23. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women
24. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
25. Effect of postmenopausal hormones on inflammation-sensitive proteins
26. Hormone replacement therapy, inflammation, and hemostasis in elderly women
27. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women
28. Hormone replacement therapy and brachial artery endothelial function in older postmenopausal women
29. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
30. Effects of statin therapy on cardiovascular events and all-cause mortality in women in the heart and estrogen/progestin replacement study
31. Hypertriglyceridemia as a cardiovascular risk factor
32. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
33. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
34. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
35. Interrelationships among subgroups of serum lipoproteins in normal human subjects
36. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women
37. Inheritance of low-density lipoprotein subclass patterns: Results of complex segregation analysis
38. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women
39. Estrogen-induced small low-density lipoprotein particles in postmenopausal women
40. Lipoprotein and cholesterol metabolism in diet-induced coronary artery atherosclerosis in primates. Role of cholesterol and fatty acids
41. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia
42. Lessons from HERS: The null and beyond
43. The Heart and Estrogerdprogestin Replacement Study (HERS)
44. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
45. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
46. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis. A randomized, controlled trial
47. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study
48. Transdermal hormone replacement therapy for secondary prevention of coronary artery disease in postmenopausal women
49. Estrogen and heart disease. Lessons to be learned from nonhuman primates
50. Estrogen in the prevention of atherosclerosis trial
51. Molecular mechanisms of estrogen action: Selective ligands and receptor pharmacology
52. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women
53. Tamoxifen and cardiac risk factors in healthy women. Suggestion of an anti-inflammatory effect
54. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis
55. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women